Portet-sur-Garonne, France

Frédéric Lieby-Muller

USPTO Granted Patents = 4 

 

Average Co-Inventor Count = 5.3

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2016-2019

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Frédéric Lieby-Muller: Innovator in Cancer Treatment

Introduction

Frédéric Lieby-Muller is a notable inventor based in Portet-sur-Garonne, France. He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds for cancer treatment. With a total of 4 patents, his work has the potential to impact the pharmaceutical industry significantly.

Latest Patents

Lieby-Muller's latest patents focus on Flavagline derivatives. These inventions relate to compounds that can exist as one of the enantiomers or a mixture of the enantiomers, along with their pharmaceutically acceptable salts and/or solvates. The primary application of these compounds is as a medicament, specifically targeting cancer treatment. Additionally, the patents include pharmaceutical compositions containing these compounds and methods for their production.

Career Highlights

Throughout his career, Frédéric Lieby-Muller has worked with prominent companies in the pharmaceutical sector, including Pierre Fabre Medicament and Pierre Fabre Médicament. His expertise in medicinal chemistry has allowed him to contribute to innovative solutions in healthcare.

Collaborations

Lieby-Muller has collaborated with notable professionals in his field, including Frédéric Marion and Michel Perez. These collaborations have likely enriched his research and development efforts, leading to advancements in cancer treatment.

Conclusion

Frédéric Lieby-Muller is a distinguished inventor whose work in Flavagline derivatives showcases his commitment to improving cancer treatment. His contributions to the pharmaceutical industry are noteworthy and reflect his dedication to innovation in medicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…